FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4253140586> ?p ?o ?g. }

• W4253140586 endingPage "1444" @default.
• W4253140586 startingPage "1434" @default.
• W4253140586 abstract "Purpose: To answer whether prophylactic panretinal photocoagulation (PRP) in ischemic central vein occlusion (CVO) prevents development of 2 clock hours of iris neovascularization or any angle neovascularization (TC-INV/ANV) or whether it is more appropriate to apply PRP only when TC-INV/ANV occurs. Methods: Multicenter randomized controlled clinical trial in eyes with ischemic CVO. Eyes were assigned to immediate prophylactic PRP (90 eyes) or to frequent close observation (91 eyes). If TC-INV/ANV developed, untreated eyes received PRP and previously treated eyes received supplemental PRP. Results: In both groups, TC-INV/ANV developed less often in prophylactically treated than untreated eyes, but the difference was not statistically significant when adjusted for baseline imbalance. Treatment of TC-INV/ANV was followed by prompt regression (within 1 month) in 18 (56%) of 32 previously untreated eyes and in 4 (22%) of 18 eyes that had had prophylactic treatment. All eyes except eight eventually stabilized without neovascularization. TC-INV/ANV was correlated with the amount of nonperfused retina (P = 0.0001) and extent of retinal hemorrhage (P = 0.03). Males were at higher risk than females for TC-INV/ANV (P = 0.01), as were patients with occlusions of less than one month duration (P = 0.01). Conclusions: Prophylactic PRP does not totally prevent TC-INV/ANV, and prompt regression of TC-INV/ANV in response to PRP is more likely to occur in eyes that have not been treated previously. The authors recommend careful observation with frequent follow-up examinations in the early months (including undilated slit-lamp examination of the iris and gonioscopy) and prompt PRP of eyes in which TC-INV/ANV develops. Purpose: To answer whether prophylactic panretinal photocoagulation (PRP) in ischemic central vein occlusion (CVO) prevents development of 2 clock hours of iris neovascularization or any angle neovascularization (TC-INV/ANV) or whether it is more appropriate to apply PRP only when TC-INV/ANV occurs. Methods: Multicenter randomized controlled clinical trial in eyes with ischemic CVO. Eyes were assigned to immediate prophylactic PRP (90 eyes) or to frequent close observation (91 eyes). If TC-INV/ANV developed, untreated eyes received PRP and previously treated eyes received supplemental PRP. Results: In both groups, TC-INV/ANV developed less often in prophylactically treated than untreated eyes, but the difference was not statistically significant when adjusted for baseline imbalance. Treatment of TC-INV/ANV was followed by prompt regression (within 1 month) in 18 (56%) of 32 previously untreated eyes and in 4 (22%) of 18 eyes that had had prophylactic treatment. All eyes except eight eventually stabilized without neovascularization. TC-INV/ANV was correlated with the amount of nonperfused retina (P = 0.0001) and extent of retinal hemorrhage (P = 0.03). Males were at higher risk than females for TC-INV/ANV (P = 0.01), as were patients with occlusions of less than one month duration (P = 0.01). Conclusions: Prophylactic PRP does not totally prevent TC-INV/ANV, and prompt regression of TC-INV/ANV in response to PRP is more likely to occur in eyes that have not been treated previously. The authors recommend careful observation with frequent follow-up examinations in the early months (including undilated slit-lamp examination of the iris and gonioscopy) and prompt PRP of eyes in which TC-INV/ANV develops." @default.
• W4253140586 created "2022-05-12" @default.
• W4253140586 date "1995-10-01" @default.
• W4253140586 modified "2023-10-16" @default.
• W4253140586 title "A Randomized Clinical Trial of Early Panretinal Photocoagulation for Ischermic Central Vein Occlusion" @default.
• W4253140586 cites W1966505307 @default.
• W4253140586 cites W2078560596 @default.
• W4253140586 cites W4236206470 @default.
• W4253140586 doi "https://doi.org/10.1016/s0161-6420(95)30848-2" @default.
• W4253140586 hasPublicationYear "1995" @default.
• W4253140586 type Work @default.
• W4253140586 citedByCount "270" @default.
• W4253140586 countsByYear W42531405862012 @default.
• W4253140586 countsByYear W42531405862013 @default.
• W4253140586 countsByYear W42531405862014 @default.
• W4253140586 countsByYear W42531405862015 @default.
• W4253140586 countsByYear W42531405862016 @default.
• W4253140586 countsByYear W42531405862017 @default.
• W4253140586 countsByYear W42531405862018 @default.
• W4253140586 countsByYear W42531405862019 @default.
• W4253140586 countsByYear W42531405862020 @default.
• W4253140586 countsByYear W42531405862021 @default.
• W4253140586 countsByYear W42531405862022 @default.
• W4253140586 countsByYear W42531405862023 @default.
• W4253140586 crossrefType "journal-article" @default.
• W4253140586 hasConcept C118487528 @default.
• W4253140586 hasConcept C126322002 @default.
• W4253140586 hasConcept C134018914 @default.
• W4253140586 hasConcept C141071460 @default.
• W4253140586 hasConcept C168563851 @default.
• W4253140586 hasConcept C2776268601 @default.
• W4253140586 hasConcept C2778271429 @default.
• W4253140586 hasConcept C2778844676 @default.
• W4253140586 hasConcept C2779829184 @default.
• W4253140586 hasConcept C2780347916 @default.
• W4253140586 hasConcept C2780394083 @default.
• W4253140586 hasConcept C2780827179 @default.
• W4253140586 hasConcept C2908627140 @default.
• W4253140586 hasConcept C535046627 @default.
• W4253140586 hasConcept C555293320 @default.
• W4253140586 hasConcept C71924100 @default.
• W4253140586 hasConceptScore W4253140586C118487528 @default.
• W4253140586 hasConceptScore W4253140586C126322002 @default.
• W4253140586 hasConceptScore W4253140586C134018914 @default.
• W4253140586 hasConceptScore W4253140586C141071460 @default.
• W4253140586 hasConceptScore W4253140586C168563851 @default.
• W4253140586 hasConceptScore W4253140586C2776268601 @default.
• W4253140586 hasConceptScore W4253140586C2778271429 @default.
• W4253140586 hasConceptScore W4253140586C2778844676 @default.
• W4253140586 hasConceptScore W4253140586C2779829184 @default.
• W4253140586 hasConceptScore W4253140586C2780347916 @default.
• W4253140586 hasConceptScore W4253140586C2780394083 @default.
• W4253140586 hasConceptScore W4253140586C2780827179 @default.
• W4253140586 hasConceptScore W4253140586C2908627140 @default.
• W4253140586 hasConceptScore W4253140586C535046627 @default.
• W4253140586 hasConceptScore W4253140586C555293320 @default.
• W4253140586 hasConceptScore W4253140586C71924100 @default.
• W4253140586 hasIssue "10" @default.
• W4253140586 hasLocation W42531405861 @default.
• W4253140586 hasOpenAccess W4253140586 @default.
• W4253140586 hasPrimaryLocation W42531405861 @default.
• W4253140586 hasRelatedWork W139291731 @default.
• W4253140586 hasRelatedWork W1988341374 @default.
• W4253140586 hasRelatedWork W1998541618 @default.
• W4253140586 hasRelatedWork W2062091766 @default.
• W4253140586 hasRelatedWork W2355803375 @default.
• W4253140586 hasRelatedWork W2403332000 @default.
• W4253140586 hasRelatedWork W2414186930 @default.
• W4253140586 hasRelatedWork W2992853244 @default.
• W4253140586 hasRelatedWork W2994033573 @default.
• W4253140586 hasRelatedWork W4290398292 @default.
• W4253140586 hasVolume "102" @default.
• W4253140586 isParatext "false" @default.
• W4253140586 isRetracted "false" @default.
• W4253140586 workType "article" @default.